[HTML][HTML] Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, X Su, K Wang, Z Lu, C Yuan, J Feng… - Journal of Experimental …, 2018 - Springer
Background Ovarian cancer is the most leading cause of death and the third most common
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
S Yao, L Li, XT Su, K Wang, ZJ Lu, CZ Yuan… - … of Experimental & …, 2018 - europepmc.org
Background Ovarian cancer is the most leading cause of death and the third most common
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
S Yao, L Li, X Su, K Wang, Z Lu… - … of Experimental & …, 2018 - search.ebscohost.com
Background: Ovarian cancer is the most leading cause of death and the third most common
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, X Su, K Wang, Z Lu, C Yuan… - … of Experimental & …, 2018 - go.gale.com
Background Ovarian cancer is a leading cause of death and the third most common
gynecologic malignancy in women [1, 2]. The 5-year survival rate of advanced stage ovarian …
gynecologic malignancy in women [1, 2]. The 5-year survival rate of advanced stage ovarian …
[HTML][HTML] Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, X Su, K Wang, Z Lu… - … of Experimental & …, 2018 - jeccr.biomedcentral.com
Ovarian cancer is the most leading cause of death and the third most common gynecologic
malignancy in women. Traditional chemotherapy has inevitable drawbacks of nonspecific …
malignancy in women. Traditional chemotherapy has inevitable drawbacks of nonspecific …
Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, XT Su, K Wang, ZJ Lu, CZ Yuan… - … of Experimental and …, 2018 - hero.epa.gov
Ovarian cancer is the most leading cause of death and the third most common gynecologic
malignancy in women. Traditional chemotherapy has inevitable drawbacks of nonspecific …
malignancy in women. Traditional chemotherapy has inevitable drawbacks of nonspecific …
[HTML][HTML] Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, X Su, K Wang, Z Lu, C Yuan… - … of Experimental & …, 2018 - ncbi.nlm.nih.gov
Background Ovarian cancer is the most leading cause of death and the third most common
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, XT Su, K Wang, ZJ Lu… - … of experimental & …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Ovarian cancer is the most leading cause of death and the third most common
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
[PDF][PDF] Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
S Yao, L Li, X Su, K Wang, Z Lu, C Yuan, J Feng, S Yan… - 2018 - jeccr.biomedcentral.com
Background: Ovarian cancer is the most leading cause of death and the third most common
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …
gynecologic malignancy in women. Traditional chemotherapy has inevitable drawbacks of …